# LenioBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/leniobio

- Industry: Biotechnology
- Headquarters: Düsseldorf, Germany
- Website: www.leniobio.com/
- Total disclosed funding: $18M
- Latest round: Series A (Nov 9, 2021)
- Investors on record: 3

## About

Based in Düsseldorf, Germany, and founded in 2016 by its CEO DR.Remberto Martis, LenioBio GmbH operates as a biotechnology company that provides disruptive protein expression technology. In?July 2025,?LenioBio GmbH?received?EUR 3.7 million?in?grant?funding?from new investor?EU4Health. LenioBio GmbH offers ALiCE, which is a cell-free protein expression platform that enables the production of proteins. It is provided with two expression vectors, pALiCE01 and pALiCE02, which are used according to the targeting of the protein of interest. It offers yields of up to 3 mg/mL of protein in batch mode and utilizes tobacco cell lysates, depleted of vacuoles. ALiCE is available as a research kit in three different sizes. The company plans to utilize the July 2025 funding to expand continuous-modular protein expression system production, increase development of cell-free biomanufacturing applications, and grow regulatory infrastructure for medicine synthesis.

## Funding rounds

- Series A, Nov 9, 2021, $13M — Bridford Investments Ltd., Citywall B.V, HELB-Invest GmbH
- Series A, Sep 16, 2019, $4.4M — Bridford Investments Ltd., Citywall B.V

## Investors

- Bridford Investments Ltd. (https://capitalatlas.ai/funds/bridford-investments-ltd) — Series A
- Citywall B.V — Series A
- HELB-Invest GmbH — Series A